Valeur202020212022202320242025Total du passif955.27 M2.93 B2.89 B2.51 B2.18 B1.3 BTotal des capitaux propres627.21 M-351.67 M-634.08 M-716.93 M-623.84 M-127.75 MTotal du passif et des capitaux propres1.58 B2.58 B2.26 B1.8 B1.56 B1.18 BDette totale427.9 M453.99 M518.54 M173.16 M176.69 M246.72 MDette nette-283.15 M-1.06 B-818.34 M-395.35 M-746.42 M-488.36 M
Novavax, Inc. - Common Stock
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.